TiumBio Submits IND for Immuno-Oncology Drug 'TU2218' Phase 1/2 Clinical Trial to US FDA
[Asia Economy Reporter Minji Lee] Tium Bio announced on the 28th that it has submitted a Phase 1/2 clinical trial plan to the US FDA to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the immuno-oncology drug TU2218 for patients with advanced cancer. The company stated, "TU2218 will also be submitted for additional clinical trials to the Korean Ministry of Food and Drug Safety as an MRCT study."
Hot Picks Today
![Samsung: "More, Faster—No Room for Complacency"... How to Maintain the "Super Gap" Amid China's Pursuit [Chip Talk]](https://cwcontent.asiae.co.kr/asiaresize/93/2025021710490034501_1739756940.jpg)
Samsung: "More, Faster—No Room for Complacency"... How to Maintain the "Super Gap" Amid China's Pursuit [Chip Talk]
- "Even If I Lose My Investment, the Government Will Cover It"... The Fund Attracting Retail Investors' Attention [Weekend Money]
- "I Turned It On Again Out of Frustration"... Chinese Youth Hooked on 20,000 Won AI Fortune-Telling Services [Z-World Now]
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
